PDS Biotech to Present Updated VERSATILE-002 Data at ESMO Congress 2024

Core Insights - PDS Biotechnology Corporation is set to present updated data from the VERSATILE-002 trial, which evaluates the first-line treatment of Versamune® HPV in combination with KEYTRUDA® for patients with HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma at the ESMO Congress 2024 [1][2] Company Overview - PDS Biotechnology is a late-stage immunotherapy company focused on enhancing the immune system's ability to target and eliminate cancers, as well as developing vaccines for infectious diseases [3] - The company plans to initiate a pivotal clinical trial in 2024 to advance its lead program targeting advanced HPV16-positive head and neck squamous cell cancers [3] - Versamune® HPV, the company's lead investigational targeted immunotherapy, is being developed in combination with a standard immune checkpoint inhibitor and in a triple combination with PDS01ADC, an IL-12 fused antibody drug conjugate [3]